Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
7.85
Dollar change
+0.17
Percentage change
2.21
%
Index- P/E- EPS (ttm)-0.65 Insider Own25.46% Shs Outstand103.11M Perf Week-5.65%
Market Cap936.94M Forward P/E- EPS next Y-1.25 Insider Trans0.00% Shs Float88.97M Perf Month-14.58%
Income-60.25M PEG- EPS next Q-0.31 Inst Own61.70% Short Float8.66% Perf Quarter-35.55%
Sales125.71M P/S7.45 EPS this Y46.05% Inst Trans-3.67% Short Ratio12.75 Perf Half Y-40.35%
Book/sh4.14 P/B1.90 EPS next Y-82.57% ROA-10.88% Short Interest7.70M Perf Year-13.45%
Cash/sh4.59 P/C1.71 EPS next 5Y- ROE-17.48% 52W Range7.46 - 13.77 Perf YTD-25.45%
Dividend Est.- P/FCF- EPS past 5Y-17.16% ROI-13.64% 52W High-42.99% Beta0.74
Dividend TTM- Quick Ratio3.98 Sales past 5Y145.27% Gross Margin- 52W Low5.23% ATR (14)0.38
Dividend Ex-Date- Current Ratio3.98 EPS Y/Y TTM-233.52% Oper. Margin-57.69% RSI (14)37.17 Volatility3.74% 5.01%
Employees343 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin-47.93% Recom1.00 Target Price17.10
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q73.58% Payout- Rel Volume0.68 Prev Close7.68
Sales Surprise235.50% EPS Surprise52.32% Sales Q/Q761.57% EarningsNov 18 BMO Avg Volume603.88K Price7.85
SMA20-3.17% SMA50-14.36% SMA200-28.69% Trades Volume408,152 Change2.21%
Date Action Analyst Rating Change Price Target Change
Oct-07-24Initiated Piper Sandler Overweight $19
Nov-02-23Initiated Cantor Fitzgerald Overweight
Mar-31-23Initiated Mizuho Buy $12
Mar-24-23Initiated Bryan Garnier Buy $16
Nov-20-20Initiated BofA Securities Buy $13
Sep-22-20Initiated Goldman Buy $17
Jul-27-20Initiated SVB Leerink Outperform $17
Jul-24-20Initiated Jefferies Buy
Nov-19-24 07:25AM
Nov-18-24 07:00AM
Nov-08-24 05:00PM
Oct-11-24 06:57AM
Oct-10-24 08:50PM
07:30AM Loading…
07:30AM
06:30AM
Oct-09-24 08:03AM
Oct-04-24 09:00AM
Sep-16-24 05:25AM
Sep-06-24 07:00AM
Aug-13-24 07:00AM
Jul-31-24 07:00AM
Jul-18-24 09:00AM
Jul-08-24 07:00AM
08:15AM Loading…
May-14-24 08:15AM
07:00AM
Mar-21-24 02:52PM
07:00AM
Mar-13-24 07:07AM
Jan-17-24 08:30PM
04:01PM
Jan-16-24 03:59AM
Nov-30-23 04:00AM
Nov-14-23 07:00AM
Nov-08-23 07:00AM
Oct-24-23 07:00AM
Sep-12-23 06:50AM
Sep-11-23 07:00AM
Aug-17-23 07:00AM
07:00AM Loading…
Aug-10-23 07:00AM
Jul-24-23 07:00AM
May-16-23 07:00AM
May-02-23 07:00AM
May-01-23 07:00AM
Apr-23-23 08:56AM
Mar-21-23 07:31AM
Nov-17-22 07:00AM
Oct-10-22 07:37AM
07:36AM
Sep-10-22 03:06AM
Aug-23-22 07:00AM
Aug-09-22 07:00AM
Jun-25-22 10:42AM
Jun-07-22 07:00AM
Jun-02-22 07:05AM
06:59AM
May-26-22 06:54AM
May-18-22 07:00AM
May-10-22 07:00AM
May-03-22 11:41AM
Apr-15-22 09:55AM
Mar-31-22 12:13PM
Mar-23-22 07:00AM
Feb-14-22 09:54AM
Dec-16-21 04:42AM
Dec-14-21 06:59AM
Nov-18-21 08:01AM
Nov-16-21 07:00AM
Nov-09-21 08:00AM
Nov-01-21 08:00AM
02:34AM
Aug-20-21 07:31AM
Aug-10-21 07:00AM
Jul-07-21 03:00AM
May-26-21 07:00AM
May-22-21 04:29AM
May-18-21 07:00AM
May-11-21 07:00AM
Apr-03-21 05:41AM
Mar-30-21 07:00AM
Mar-17-21 07:00AM
Mar-02-21 03:00AM
Dec-18-20 04:30PM
Dec-02-20 07:00AM
Nov-10-20 07:00AM
Oct-29-20 07:00AM
Oct-14-20 06:19PM
Oct-05-20 11:23AM
Sep-30-20 10:01AM
Sep-29-20 07:00AM
Sep-15-20 07:00AM
Sep-10-20 07:00AM
Sep-03-20 07:00AM
Aug-18-20 07:00AM
Aug-06-20 07:00AM
Jul-09-20 07:00AM
Jul-02-20 07:00AM
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.